Genmab — November 2018

[Bulder]

E L: From Lyra: After induction, pts could undergo autologous stem cell transplantation (ASCT) - so they were also candidates. I don't think more frail than Griffin pts.

[Bulder]

The same goes for the small Irish cybord study: newly diagnosed MM (NDMM) pts eligible for ASCT

[Bulder]

The excitement in the conclusion is modest: Dara-CyBorD was active and well tolerated

[Bulder]

I'll ask Winkel if the results are worth a large phase 3 study.

[E_L]

yes, true, i was more thinking compared to the studies we already now, the Polux/ Alcyone/Maia etc, sry

[E_L]

But would be a good question...

[E_L]

it may have a different toxicity profile and therefore still be good for some patients even if the results would be a bit disapointing?

[E_L]

the more options the better i guess…

[Bulder]

I see. No doubt that Griffin pts are better than Maia pts. But equal to Cass pts.

[Bulder]

I remember Michael E O'Dwyer in a video saying that DRd or DRVd suffers from a considerable financial toxicity. The Irish can't afford it.

[Solsen]

In 2023 R goes off patent...

[Bulder]

Regarding Maia and Griffin. In Griffin we had 100% vgpr or better. I don't think we'll se that in Maia. But hopefully 100% PR or better.

[E_L]

it looks like Cyclophosphamide is a lot cheaper? Not sure if the dosing is 100% correct, but differnce looks large
http://ascopubs.org/doi/pdfdirect/10.1200/EDBK_200867

[gentogen]

Det lille CybordD har fulgt patienterne længere (post asct): "Responses deepened post ASCT with 100% achieving ≥ VGPR and 62% achieving ≥ CR. Based on EBMT criteria the CR/nCR rate post ASCT was 92%. Post ASCT PET-CT scans were consistent with complete metabolic response in all 13 patients". Ved ikke, jvad der ellers ses, men lyder vel OK.

[Solsen]

HR er tilsyneladende med seneste opdatering 0,43 i Alcyone - på ASCO stod der 0,5.

[JørgenVarnæs]

hold da op - det er da en udvikling, der er til at mærke. Så er det bare om at de andre fase 3 data kan udvikle sig på sammen måde/retning

[Bulder]

Og endnu mere bemærkelsesværdigt idet pfs for VMP er øget med 1 måned http://www.multiplemyelomahub.com/medical-information/ash-2017-phase-iii-alcyone-clinical-trial-daratumumab-plus-bortezomib-melphalan-and-prednisone-d-vmp-in-ndmm-patients-ineligible-for-transplant

[Solsen]

https://ash.confex.com/ash/2018/webprogram/start.html#srch=words|Adct 301|method|and|pge|1|byDayany|any|bySymposiumany|any|byAudienceany|any 5 orale præsentationer med ADCT 301 ! Mon ikke Genmab skulle have benyttet opt.in.

[Solsen]

Ja den ekstra måned er også interessant. Så det kan godt rykke lidt på tallene med tiden....

[Bulder]

Hvis Maia gør ligeså er vi nede i 0,4'erne til næste år.